5
Noble Explochem
506991 BSE
Noble Explochem
Commodities BSE: 506991 Chemicals & Petrochemicals
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
2- Company has low interest coverage ratio.
- Contingent liabilities of Rs.26.3 Cr.
Growth Rate
Net Income Growth
-97% lower than
3Y
Quarterly Results
| Particulars | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.22 | 0.38 | 0.08 | 0.13 | 0.12 | 0.26 | 0.18 | 0.17 | 0.25 | 0.6 | 0.23 | 0.24 | 0.4 |
| Operating Profit | -0.22 | -0.38 | -0.08 | -0.13 | -0.12 | -0.26 | -0.18 | -0.17 | -0.25 | -0.6 | -0.23 | -0.24 | -0.4 |
| Other Income | 0 | 0.04 | 0 | 0 | 0 | 0 | 0 | 0 | 0.15 | 0.07 | 0 | 0.01 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.22 | -0.34 | -0.08 | -0.13 | -0.12 | -0.26 | -0.18 | -0.17 | -0.1 | -0.53 | -0.23 | -0.24 | -0.4 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.22 | -0.34 | -0.08 | -0.13 | -0.12 | -0.26 | -0.18 | -0.17 | -0.1 | -0.53 | -0.23 | -0.24 | -0.4 |
| EPS in Rs | -0.11 | -0.18 | -0.04 | -0.07 | -0.06 | -0.14 | -0.09 | -0.09 | -0.05 | -0.28 | -0.12 | -0.12 | -0.21 |
Profit & Loss
| Particulars | Mar 2007 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11.93 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 35.04 | 10.07 | 0.51 | 13.62 | 0.99 | 0.89 | 0.84 | 0.82 | 0.84 | 0.91 | 0.59 | 1.2 | 1.47 |
| Operating Profit | -23.11 | -10.07 | -0.51 | -13.62 | -0.99 | -0.89 | -0.84 | -0.82 | -0.84 | -0.91 | -0.59 | -1.2 | -1.47 |
| OPM % | -193.71% | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Income | 0.96 | 0.26 | 2.04 | 0.01 | 0.02 | 0.24 | 0.09 | 0 | 0.23 | 0.04 | 0.04 | 0.22 | 0.08 |
| Interest | 3.04 | 0.62 | 0 | 0 | 0.04 | 0.11 | 0.25 | 0.01 | 0.03 | 0 | 0 | 0 | 0.01 |
| Depreciation | 1.41 | 1.25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -26.6 | -11.68 | 1.53 | -13.61 | -1.01 | -0.76 | -1 | -0.83 | -0.64 | -0.87 | -0.55 | -0.98 | -1.4 |
| Tax % | 3.8% | -12.76% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | -27.61 | -10.19 | 1.53 | -13.61 | -1.01 | -0.76 | -1 | -0.83 | -0.64 | -0.87 | -0.55 | -0.98 | -1.4 |
| EPS in Rs | -14.36 | -5.3 | 0.8 | -7.08 | -0.53 | -0.4 | -0.52 | -0.43 | -0.33 | -0.45 | -0.29 | -0.51 | -0.73 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2007 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19.21 | 19.21 | 19.21 | 19.21 | 19.21 | 19.21 | 19.21 | 19.21 | 19.21 | 19.21 | 19.21 | 19.21 |
| Reserves | -13.96 | -34.84 | -33.31 | -46.72 | -46.73 | -45.42 | -44.11 | -44.48 | -44.96 | -45.8 | -46.35 | -47.33 |
| Borrowings | 27.57 | 34.89 | 35.05 | 35.07 | 35.09 | 34.94 | 33.69 | 34.12 | 34.1 | 34.45 | 34.95 | 35.02 |
| Other Liabilities | 11.36 | 14.4 | 12.33 | 12.52 | 12.44 | 11.44 | 11.57 | 11.4 | 11.72 | 12.01 | 12.15 | 12.99 |
| Total Liabilities | 44.18 | 33.66 | 33.28 | 20.08 | 20.01 | 20.17 | 20.36 | 20.25 | 20.07 | 19.87 | 19.96 | 19.89 |
| Fixed Assets | 23.1 | 18.78 | 18.78 | 18.78 | 18.78 | 18.78 | 18.78 | 18.78 | 18.78 | 18.78 | 18.78 | 18.7 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.1 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 20.98 | 14.83 | 14.45 | 1.25 | 1.18 | 1.34 | 1.53 | 1.47 | 1.29 | 1.09 | 1.18 | 1.19 |
| Total Assets | 44.18 | 33.66 | 33.28 | 20.08 | 20.01 | 20.17 | 20.36 | 20.25 | 20.07 | 19.87 | 19.96 | 19.89 |
Cash Flow
| Particulars | Mar 2007 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -3.7 | — | — | -0.23 | -1.08 | -1.95 | -2.26 | -1 | -0.33 | -0.56 | -0.45 | -0.18 |
| Investing | -0.98 | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.01 | 0.09 |
| Financing | 3.48 | — | — | 0.22 | 1.07 | 2.07 | 2.37 | 1.02 | 0.14 | 0.38 | 0.5 | 0.07 |
| Net Cash Flow | -1.2 | — | — | -0.01 | -0.01 | 0.12 | 0.11 | 0.01 | -0.19 | -0.18 | 0.04 | -0.03 |
| Free Cash Flow | -4.95 | — | — | -0.23 | -1.08 | -1.95 | -2.26 | -1 | -0.33 | -0.56 | -0.46 | -0.09 |
| CFO/OP | 12 | — | — | 2 | 109 | 219 | 269 | 122 | 39 | 62 | 76 | 15 |
Ratios
| Particulars | Mar 2007 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 96.68 | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Days | 74.96 | 0 | — | — | — | — | — | — | — | — | — | — |
| Days Payable | 42.65 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Conversion Cycle | 129 | — | — | — | — | — | — | — | — | — | — | — |
| Working Capital Days | 377 | — | — | — | — | — | — | — | — | — | — | — |
| ROCE % | -51.93% | — | 7.61% | -95.48% | -12.82% | -7.98% | -8.56% | -9.3% | -7.09% | -10.73% | -7.02% | -13.32% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Noble Explochem insights
51 extracted metrics + investor summaries across FY07–FY19.
Documents
1
Unaudited Standalone Financial Results For The Half Year Ended September 30, 2025 Along With The Limited Review Report.
14 Nov 2025 - Unaudited standalone results for half year ended Sep 30, 2025 with limited review report filed. 14 Nov 2025 - Unaudited standalone results for half year ended Sep 30, 2025 with limited review report filed.
2
Intimation For Appointment Of Internal Auditor For FY 2025-26
14 Nov 2025 - Board appointed M/s. R. M. Hariyani & Co. as internal auditor for FY2025-26 on November 14, 2025. 14 Nov 2025 - Board appointed M/s. R. M. Hariyani & Co. as internal auditor for FY2025-26 on November 14, 2025.
3
Statement Of Deviation(S) Or Variation(S) Of Funds Raised Through Public Issue
14 Nov 2025 - IPO funds deviation statement filed as on Sep 30, 2025 for Broach Lifecare (Scrip 544231) 14 Nov 2025 - IPO funds deviation statement filed as on Sep 30, 2025 for Broach Lifecare (Scrip 544231)
4
Intimation For Appointment Of Secretarial Auditor For The FY 2025-26
14 Nov 2025 - Appointed N R Shah and Co as Secretarial Auditor for FY2025-26 on 14 November 2025. 14 Nov 2025 - Appointed N R Shah and Co as Secretarial Auditor for FY2025-26 on 14 November 2025.
5
Intimation Of Unaudited Standalone Financial Results For The Half Year Ended September 30, 2025 Along With The Limited Review Report
14 Nov 2025 - Unaudited standalone results for half year ended 30 Sep 2025; limited review report submitted 14 Nov 2025. 14 Nov 2025 - Unaudited standalone results for half year ended 30 Sep 2025; limited review report submitted 14 Nov 2025.
Frequently Asked Questions about Noble Explochem
What does Noble Explochem Ltd do?
Noble Explochem is principally engaged in the production of explosives. The Company manufactures emulsion-based explosives and petrochemicals.
Where is Noble Explochem Ltd (506991) listed?
Noble Explochem Ltd trades under code 506991 on the BSE.
Which sector does Noble Explochem Ltd belong to?
Noble Explochem Ltd is classified under the Commodities sector, in the Chemicals & Petrochemicals industry.
Company Information
Noble Explochem is principally engaged in the production of explosives. The Company manufactures emulsion-based explosives and petrochemicals.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/506991.md for Noble Explochem Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.